Efficacy and safety of porous hydroxyapatite/type 1 collagen composite implantation for bone regeneration: A randomized controlled study
Shinichi Sotome(Tokyo Medical and Dental University), Kenichi Shinomiya(Yokohama Municipal Minato Red Cross Hospital), Masafumi Ishizuki(Tsuchiura Kyodo General Hospital), Seiichi Matsumoto(Fukuda Denshi (Japan)), Hideo Morioka, Satoshi Abe(Tottori University), Takashi Nakamura(Jikei University School of Medicine), Keisuke Ae(The Cancer Institute Hospital), Yasuo Beppu(Tokyo National Hospital), Atsushi Okawa(Research Institute of Economy, Trade and Industry)
Cited by 82
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
IL-1 and TNF -initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis
|International Immunology|2011|326
Clear Cell Sarcoma of Soft Tissue
|The American Journal of Surgical Pathology|2008|283
Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A
|Proceedings of the National Academy of Sciences|2018|264
The Blimp1–Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis
|The Journal of Experimental Medicine|2010|199